Siltuximab + Epcoritamab
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Hodgkin Lymphoma
Conditions
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Trial Timeline
Jan 14, 2025 → Sep 1, 2028
NCT ID
NCT06447376About Siltuximab + Epcoritamab
Siltuximab + Epcoritamab is a phase 1 stage product being developed by AbbVie for Non-Hodgkin Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06447376. Target conditions include Non-Hodgkin Lymphoma, Cytokine Release Syndrome.
What happened to similar drugs?
8 of 20 similar drugs in Non-Hodgkin Lymphoma were approved
Approved (8) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06447376 | Phase 1 | Recruiting |
Competing Products
20 competing products in Non-Hodgkin Lymphoma